Posts by: Alice Melão

News

An investigational antibody-drug conjugate, TRPH-222, effectively reduced tumor burden in mice with diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL), and is well-tolerated in non-human primates, a new ... Read more

December 1, 2017December 1, 2017

Eureka Technologies Receives FDA’s OK to Move T-cell Therapy into Clinical Trials

News

The U.S. Food and Drug Administration (FDA) has approved the T-cell therapy ET190L1-ARTEMIS to move into clinical trials for the treatment of relapsed and refractory CD19-positive non-Hodgkin’s lymphoma (NHL). Following the ... Read more

November 29, 2017November 29, 2017

FDA to Review Mogamulizumab as Treatment for Cutaneous T-cell Lymphoma

News

The U.S. Food and Drug Administration (FDA) will review the use of mogamulizumab as a treatment for cutaneous T-cell lymphoma (CTCL) in patients who received at least one prior line of ... Read more

November 7, 2017November 7, 2017

Study Links Early Progression to Poorer Survival Outcomes in Follicular Lymphoma Patients

News

New data from the GALLIUM Phase 3 trial (NCT01332968) shows that follicular lymphoma patients who progress within two years of immunochemotherapy have a 26-fold increased risk of death, compared to those ... Read more

October 27, 2017October 27, 2017

FDA Clears Way for Denovo to Launch Phase 3 Trial of DB102 for DLBCL Patients in US

News

The U.S. Food and Drug Administration (FDA) has given Denovo Biopharma the green light to advance its investigational drug DB102 into a Phase 3 clinical trial for diffuse large B-cell lymphoma ... Read more

October 23, 2017October 23, 2017

French Researchers Develop Quick, Cost-Effective Test to Detect DLBCL Subtypes

News

A newly developed assay can rapidly and accurately recognize different subtypes of diffuse large B-cell lymphoma (DLBCL), providing useful diagnostic information that could help doctors match tumors with the right ... Read more

October 20, 2017October 21, 2017

Researchers Identify Enzyme as New Target for Treating Classical Hodgkin’s Lymphoma

News

An enzyme called monoamine oxidase-A (MAO-A) contributes to the growth of classical Hodgkin’s lymphoma cells but not other lymphoma cells, a study reports. It also indicated that a combination of ... Read more

October 18, 2017October 18, 2017

Incysus Advances T-Cell Therapy into Phase 1 Trial for Blood Cancers

News

Incysus and the University of Alabama at Birmingham (UAB) are advancing the company’s investigational gamma-delta (γδ) T-cell therapy into a Phase 1 clinical study for the treatment of leukemia and lymphoma ... Read more

October 12, 2017

Clinical Trial Evaluating Resminostat as Maintenance Therapy in CTCL Is Enrolling Participants

News

A Phase 2 trial is currently enrolling participants to evaluate 4SC‘s investigational therapy resminostat as a maintenance therapy for advanced-stage cutaneous T-cell lymphoma (CTCL). The RESMAIN study (NCT02953301) is being conducted at about ... Read more

October 2, 2017October 2, 2017

Incysus Seeks FDA Approval to Start Blood Cancer Trials for Its γδ T-Cell Immunotherapy

News

Incysus has filed an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) to start clinical development of its expanded and activated allogeneic gamma-delta (γδ) T-cell ... Read more